Sorrento Therapeutics Competitors and Similar CompaniesClear all
Sorrento Therapeutics's competitors and similar companies include Celyad, Alnylam, Luna Innovations and Merus.
 Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Luna Innovations Luna Innovations is a company that manufactures and develops fiber optic measurement systems. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. | |
Founding Date | Founding Date 2006 | Founding Date 2007 | Founding Date 2002 | Founding Date 1990 | Founding Date 2003 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ San Diego, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations Roanoke, US HQ Cologne, DE Dubai, AE Camberley, GB Dorchester, GB Portishead, GB Ann Arbor, US see more | Locations Utrecht, NL HQ Cambridge, US | |
Employees | Employees 31019% decrease | Employees 17 | Employees 1,32324% increase | Employees 337 | Employees 260 |
Valuation ($) | Valuation ($) 1.5 m | Valuation ($) 11.8 m | Valuation ($) 36.5 b | Valuation ($) 59.2 m | Valuation ($) 3.6 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) €21k (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $109.5m (FY, 2022) | Revenue (est.) $36.1m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods €8k (FY, 2025) | Cost of goods $677.2m (FY, 2025) | Cost of goods $43m (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €5.9m (FY, 2025) | Gross profit $3b (FY, 2025) | Gross profit $66.5m (FY, 2022) | Gross profit $36.1m (FY, 2024) |
Net income | Net income ($577.8m) (FY, 2022) | Net income €830k (FY, 2025) | Net income $313.7m (FY, 2025) | Net income $9.3m (FY, 2022) | Net income ($215.3m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 42.6m | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 13.1m | Total funding raised $ 149.3m |
For sources of this data, please see the company profile
View Company Profiles
Celyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyLuna Innovations
HQ
Roanoke, US
Employees
337
Luna Innovations is a company that manufactures and develops fiber optic measurement systems.
View companyMerus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View company